Spinout equity norms
The core idea#
When a company is built on university IP, the university usually takes shares as part of the price. How many matters more than founders expect: every percentage point the university holds at formation is a point that founders and future employees don't, and too large a stake can make the company hard to fund. Norms have shifted a lot since 2023. In the UK, published guidance now puts university stakes at 10–25% for IP-heavy spinouts and 10% or less for others; US standard terms often sit in single digits; Indian institutes commonly take low single digits.
This playbook gives you the current benchmarks by country, explains what should push the number up or down, covers the terms that matter beyond the percentage, and shows how to negotiate.
Stage: minus-one to pre-seed · Lens: Deeptech · Reading time: about 30 minutes
Who this is for#
- Academic founders about to agree a spinout deal.
- Business co-founders and early investors assessing a spinout's cap table.
- TTO staff who want to understand how founders and investors see the numbers.
What you leave with#
- Benchmarks for the UK, US and India, with sources.
- A cap table model showing what the university's stake means at Series A.
- A list of factors that justify a higher or lower stake.
- A negotiation plan and scripts.
Why the university's stake matters#
Investors care about the founders' combined stake at the Series A, because founders who own too little lose motivation and are harder to keep. The USIT software guide built its recommendations on the expectation that founders should own at least 50% of the company at Series A (Global Venturing). Every point the university takes at formation, and especially any anti-dilution protection, comes out of that.
A simple model#
Assumptions (illustrative): at seed, new investors take 20% and a 10% option pool is created; at Series A, new investors take 20% and the pool is topped up by 5%. Everyone existing is diluted equally unless the university has anti-dilution.
| University stake at formation |
Founders at formation |
Founders after seed |
Founders after Series A |
University after Series A |
|---|---|---|---|---|
| 25%, no anti- dilution |
75% | 52.5% | 39.4% | 13.1% |
| 10%, no anti- dilution |
90% | 63.0% | 47.3% | 5.3% |
| 10%, anti-dilution through seed |
90% | 60.0% | 45.0% | 7.5% |
| 5%, no anti- dilution |
95% | 66.5% | 49.9% | 2.6% |
What the model shows#
- A 25% stake puts founders well below 50% by Series A in an ordinary financing path. That is the investor concern behind the UK review.
- Anti-dilution costs founders more than the headline suggests. It shifts dilution from the university onto founders until the threshold is reached.
- Even at 5%, founders are only just at 50% after two rounds of this size. Larger rounds, which are common in deeptech, push them lower. This is why investors look at the university stake together with how much capital the company will need.
The other side of the argument#
Not all evidence says university stakes hurt fundraising. A study of 650 UK spinouts from 2010 to 2021 by Oxford's Saïd Business School found an average university stake of 31% and concluded that the stake had limited effect on whether spinouts raised money (Saïd Business School). A 2024 University of Cambridge report also examined the relationship between founding equity and investment using TTO data from 15 universities (Cambridge IfM). Even so, founder surveys report strong dissatisfaction with high stakes (Sifted), and UK policy has moved decisively towards lower stakes.
UK norms#
The UK has the most published data and the most active policy debate, and its benchmarks are increasingly used elsewhere.
The USIT guide and the 2023 review#
TenU's University Spinout Investment Terms (USIT) guide, launched in April 2023 (Browne Jacobson), recommends university stakes of roughly 10–25% for IP-intensive sectors such as life sciences, and 10% or less for less IP-intensive spinouts (CASRAI). A separate USIT guide for software spinouts without patents recommends 5–10% (Science|Business). The government's Independent Review of University Spin-out Companies, published on 21 November 2023, endorsed USIT as the starting point, and the government accepted all its recommendations (Browne Jacobson).
What has happened since#
- Adoption. By late 2024, 49 universities in England, Wales and Scotland had adopted guidelines of 10–25% for life science spinouts (Global Venturing).
- Actual stakes fell. The Royal Academy of Engineering's Spotlight on Spinouts found the average university stake fell to 16% in 2024 from 22% in 2023 (RAEng), a ten-year low of 16.1%; the median for hardware companies fell from 21.7% to 19.1% (RAEng report).
- Founder shares are uneven. The 2026 edition reported the first analysis of founder shareholdings and found them typically unequal and highly variable (RAEng).
Selected university policies#
| University | Policy | Notes |
|---|---|---|
| Oxford | 80% founding team, 20% university in nearly all cases; 90/10 in some conditions |
In force since September 2021; university takes ordinary shares with no anti-dilution ( OUI). Student-only teams using university IP: 90/10 |
| Southampton | 90/10 for knowledge-intensive spinouts; 95/5 for others |
Presumptive split from 31 May 2024 |
| King's College London |
Founders keep 85–100%; 10% for patentable non-pharmaceutical technology |
July 2026, replacing a fixed 80% founder share |
| University |
Policy | Notes | |
|---|---|---|---|
| S norms S universities publis tandard terms show niversities took abo eview found the US a Science |
Business). C Cambridge |
h fewer fixed equity p the range. A founder s ut four times the equit nd UK positions broad ompare whole packag Uses USIT ranges: 10–25 0–5% royalty |
olicies, but licence data urvey by Air Street Cap y of US institutions ( Sift ly similar once the full d es, not just equity. % equity, Cambridge create the |
| Source | University equity | Anti-dilution | Notes |
| Gunderson Dettmer analysis of university licences |
Median 4.2%; present in 57% of licences |
In 83% of licences with equity; median threshold $10 million raised |
Royalties and fees in addition (playbook 2.07) |
| Carnegie Mellon standard terms |
6% exclusive (5% non-exclusive) for patented technology; 3% for software |
Up to $2 million raised |
2% royalty on patented technology; none on software |
| University of Missouri express licence |
None | — | University takes a share of sublicence income instead |
| Typical biotech | Under 5% | Through a | Royalties and |
| guidance( Guide to |
reasonable level of | milestones in | |
| Biotech Startups) | funding | addition |
US norms#
US universities publish fewer fixed equity policies, but licence data and published standard terms show the range. A founder survey by Air Street Capital suggested UK universities took about four times the equity of US institutions (Sifted), while a later review found the US and UK positions broadly similar once the full deal is considered (Science|Business). Compare whole packages, not just equity.
US universities more often take equity as part of the licence fee and add royalties, so a 5% stake plus a 2–3% royalty can cost a product company more than a higher equity stake with no royalty. Model both.
India norms#
Indian institutes generally take smaller stakes than UK universities, and several now publish fixed terms.
| Source | University stake | Notes |
|---|---|---|
| National Innovation and Startup Policy (Ministry of Education guideline) |
2–9.5% depending on the support the institute provides |
A national framework that many institutes have adopted |
| IIT Kharagpur (2026 policy) | 3% for the founder's own technology; 5% for other institute technology |
Equity-based licensing |
| IIT Delhi | Up to 3% of sales turnover during incubation, plus equity held by FITT |
Revenue share rather than equity alone |
| IIT Kanpur | Equity, revenue share or a combination, for assigned IP |
Negotiated case by case |
| IISER Kolkata | Equity, upfront or milestone payments, licence fee, or a combination; equity held by its RISE Foundation |
Equity held through a separate entity |
Points specific to India#
- Two stakes, two holders. The institute (for the IP) and its incubator or Section 8 company (for incubation support) may each take equity. Add them together when you model the cap table.
- Incubation equity. Incubators often take a separate small stake or a revenue share for space, seed grants and services. Ask whether it is charged in addition to the IP stake. Government-funded IP. Licences of government-funded IP carry government rights (playbook 2.01), whatever the equity terms.
- Foreign investment. If the company may later move its holding company abroad ("flip", playbook 4.03), check how the institute's stake would be treated.
What should move the number#
Within published ranges, the stake should reflect what the institution contributes. Oxford, for example, justifies its stake by providing the environment where the IP was developed, permission for academics to be involved while employed, protection compared with a non-university entrepreneur, support with the process, and the benefit of the university's name (OUI). Use those factors, and the ones below, to argue for a specific point in the range.
| Factor | Pushes the stake up | Pushes it down |
|---|---|---|
| IP intensity | Strong patents at the core of the product (life sciences, new materials) |
Software, know-how, or IP that could be designed around |
| Stage of the technology |
Proven, well-developed technology |
Early, unproven technology needing years of company- funded work |
| Institutional support |
Proof-of-concept funding, incubation, lab access, patent costs already paid |
Founders paid their own costs or brought in outside funding |
| Other payments | No royalty or fees | Royalties, upfront fees or a share of sublicence income on top |
| Founder contribution |
Inventors will stay in academic roles |
Founders leave their jobs to work full-time; outside founders bring business skills |
| Capital needs | Capital-light business | Capital-heavy deeptech needing large rounds before revenue |
The USIT approach links the university's equity and royalty to the maturity and market readiness of the technology (Cambridge Enterprise). That gives you a principled argument: "Given that the technology is at TRL 3, needs our full-time work for four years, and you are also taking a royalty, we propose the bottom of the range."
Beyond the percentage#
Two deals with the same headline percentage can be very different. Check these terms.
| Term | Founder-friendly | Watch out for |
|---|---|---|
| Share class | Ordinary shares, the same as founders. Oxford takes ordinary shares( OUI) |
Preferred shares with extra rights |
| Anti-dilution | None, as at Oxford, which is | Protection through the Series A |
| diluted at the same rate as | or beyond; US licences in one | |
| founders ( OUI); or ending at a |
analysis had a median threshold | |
| modest threshold, such as | of $10 million ( Gunderson |
|
| CMU's $2 million ( CMU) |
Dettmer) |
| Term | Founder-friendly | Watch out for |
|---|---|---|
| Pre-emption (pro rata) rights |
The right to invest in later rounds, which costs founders nothing |
Rights to block or approve rounds |
| Board seats | None, or an observer seat with a sunset. Investors often accept observers with a sunset ( Orrick) |
A full board seat held by TTO staff; UK founders have complained about this ( Sifted) |
| Consent rights | Standard minority protections only |
Vetoes over fundraising, hiring or strategy |
| Information rights | Annual accounts and periodic updates |
Detailed operating reports beyond what investors receive |
| Exit treatment | Same as other ordinary shareholders |
Special payouts or liquidation preference |
A lower stake with heavy rights can be worse than a slightly higher stake held as plain ordinary shares.
Splitting the founders' share#
Once the university's stake is set, the founders must divide the rest. In spinouts this usually means academic inventors, students or postdocs who will go full-time, and sometimes business founders who join from outside. The UK review encouraged founders to split equity in a way that recognises both contributions to creating the IP and the need to reward the people who will build the company (CIC), and the Royal Academy of Engineering has called for more equitable splits between universities, senior faculty and spinout leadership (Oxford).
Principles#
- Reward future work more than past work. The IP is already paid for through the university's stake. Most of the company's value will come from the next 5–10 years.
- Full-time founders should hold most of the founder equity. A professor who will stay in post and advise should usually hold less than the full-time CEO and CTO. Vest everything. Founder shares should vest over time, typically four years, so that someone who leaves early doesn't keep a large stake (playbook 3.06).
- Leave room. A future CEO or key hires will need equity; the option pool comes out of everyone's share.
An illustrative split (university at 10%)#
| Person | Role | Share of company at formation |
|---|---|---|
| Full-time CEO (business founder) |
Runs the company | 30% |
| Full-time CTO (postdoc inventor) |
Leads technology | 30% |
| Professor (inventor) | Scientific advisor, part- time |
15% |
| Second student inventor | Joins full-time after PhD | 15% |
| University | IP and support | 10% |
The right split depends on each person's role, commitment and risk. Playbook 3.05 covers the frameworks in detail.
How to negotiate#
Where an institution has a fixed policy, as Oxford, Southampton, KCL and several IITs now do, there is little to negotiate on the percentage, and that is a good thing: it removes months of argument. Oxford says its fixed policy removes case-by-case negotiation and makes formation faster and more transparent (Oxford). Focus instead on the terms beyond the percentage and on the licence. Where there is no fixed policy, use this approach.
Before the meeting#
- Find the institution's policy, and the policies of three peer institutions.
- Model the cap table through Series A with realistic round sizes for your sector.
- Classify your spinout using the factors table above, and pick a target and a walk-away number.
- Talk to a likely lead investor. Their view of an acceptable stake is your strongest argument.
- Prepare the whole package: equity, royalty, fees, anti-dilution and rights together (playbook 2.07).
In the meeting#
- Anchor on published norms, not on what you'd like. "USIT puts IP-heavy spinouts at 10–25%; our technology is early-stage and needs heavy capital, so we propose 10%."
- Trade, don't concede. A higher equity stake for no royalty; a lower stake for a slightly higher sublicence share.
- Make the investor's view visible. "Our lead investor has said a stake above 15% would be a problem for the seed round."
- Ask what the stake pays for. If the institution offers proof-of-concept funding, lab access or incubation, that supports a higher number; if not, a lower one.
- Get anti-dilution and board rights settled together with the percentage, so you don't agree a number and then lose ground on the rest.
Scripts#
Opening proposal (email)
Thank you for the draft terms. Before we respond in detail, here is how we're
thinking about equity.
Our technology is at an early stage and will need about [amount] over [n]
years before revenue. Our modelling
(attached) shows that at [X]% the founders would hold [Y]% at Series A, below
the level our likely investors
expect. Published norms for comparable spinouts are [range, with source].
We'd propose [Z]%, held as ordinary
shares without anti-dilution, alongside the royalty terms in your draft. We'd
be glad to discuss.
If the institution won't move on the percentage
We understand the [X]% stake is set by policy. To make the deal work for our
investors, could we agree:
(1) ordinary shares without anti-dilution, or anti-dilution ending at [threshold];(2) an observer seat rather than a board seat, ending at the Series A; and (3) [royalty / sublicence share] at [level]?
Case files#
The UK spinout review (2023): what drove the change
The review led by Prof. Irene Tracey and Dr Andrew Williamson found that most spinouts took 4–12 months to form, and that negotiations on university equity started at an average of 34% (Mathys & Squire). Founder surveys run by Air Street Capital had reported that UK universities took more than double the equity of EU universities and placed TTO staff on spinout boards more often (Sifted). The review recommended USIT as the starting point, and the government accepted all its recommendations (GOV.UK). Within about a year, 49 universities had adopted lower ranges (Global Venturing), and the average stake fell to 16% in 2024 (RAEng).
Lesson: published data and founder voices changed the norm. Bring data to your negotiation; it works.
Oxford (2021): a fixed split to end negotiation
Oxford's Council agreed a spinout equity policy in July 2021, operational from September 2021: 80% for the founding team and 20% for the university in nearly all cases, with 90/10 in some conditions (Oxford). The university takes ordinary shares with no anti-dilution (OUI). At the time, the UK average was 31%, well above Oxford's 20% (OUI).
Lesson: a fixed policy at a moderate level, with clean share terms, may be better for founders than a lower number reached after months of negotiation with anti-dilution attached.
King's College London (2026): moving below 20%#
In July 2026 KCL replaced its fixed 80% founder share with a range of 85–100%, with the university's stake set by the type of technology: for example, 10% for patentable nonpharmaceutical technologies such as engineering, medical technology, robotics and advanced materials (KCL).
Lesson: policies keep moving downwards. Check the current version, not last year's.
IIT Kharagpur (2026): low, fixed and simple#
IIT Kharagpur's 2026 policy sets equity-based licensing at 3% for a founder's own technology and 5% for other institute technology (IIT Kharagpur).
Lesson: Indian institutes are publishing simple, low, fixed terms. Use them as benchmarks when negotiating elsewhere in India.
Mistakes and how to recover#
| Mistake | Why it hurts | How to recover |
|---|---|---|
| Negotiating the percentage without modelling dilution |
You don't see what it means at Series A |
Build the model before the first meeting |
| Accepting anti-dilution through the Series A |
Founders absorb the university's dilution |
Ask for none, or a low threshold such as $2 million |
| Forgetting the incubator's separate stake |
Total institutional ownership is higher than you think |
Add all institutional stakes together |
| Agreeing equity, then losing on royalties and rights |
The total cost is higher than expected |
Negotiate the whole package together |
| Giving most founder equity to the professor |
Full-time founders under- rewarded; investors worry |
Split by future role and commitment; vest everything |
| Using out-of-date benchmarks |
Weak arguments | Use the latest data (Spotlight on Spinouts, published policies) |
| Treating the TTO as an opponent |
Slower, harder deals | Present the case as making the spinout fundable, which is the TTO's goal too |
| Signing before talking to investors |
Investors ask for changes later |
Get a likely lead's view first |
Existing playbooks to read, and sources#
Read next#
- TenU's USIT guides for life sciences and for software (Cambridge Enterprise).
- Royal Academy of Engineering, Spotlight on Spinouts (annual), with equity data by university and company type (RAEng 2025 report).
- Independent Review of University Spin-out Companies and the government response (GOV.UK).
- spinout.fyi, Nathan Benaich's crowdsourced database of spinout terms reported by founders (Times Higher Education).
- Your institution's startup policy and its peers' policies.
Related playbooks in this library#
2.01 Who owns your invention · 2.03 Working with the TTO · 2.07 Licence anatomy · 2.10 Negotiating with a university · 2.12 Professor as co-founder · 3.05 Founder equity splits · 3.06 Vesting · 5.19 Cap table modelling · 14.23 Cap table hygiene before seed
Sources#
- Global Venturing: software founders should keep 90–95%
- Global Venturing: UK universities adopt lower equity
- CASRAI: university spinout equity split
- Science|Business: USIT software guide
- Science|Business: UK universities take lower stakes
- Browne Jacobson: update on the spinout review
- Mathys & Squire: the spinout review
- GOV.UK: Independent review of university spin-out companies
- CIC / Business Weekly: review recommendations
- RAEng: average stakes fall (2025)
- RAEng: Spotlight on Spinouts 2025 report
- RAEng: Spotlight on Spinouts 2026
- Oxford: spinout equity policy FAQ
- OUI: who gets equity in a spinout
- OUI: Saïd Business School study response (2023)
- Oxford: 2025 spinout rankings
- Saïd Business School: university stakes and fundraising
- Cambridge IfM: Spinning out success (2024)
- Sifted: UK spinout review survey
- King's College London: founder equity policy (2026)
- Cambridge Enterprise: the USIT Guide
- Gunderson Dettmer: university licence presentation (2024)
- Carnegie Mellon: startup licence terms
- University of Missouri: express licence guidelines
- Guide to Biotech Startups: licensing from universities
- Orrick: university licensing for startups (2024)
- NISP 2019 summary
- IIT Kharagpur entrepreneurship policy 2026
- IIT Delhi: outside professional engagement
IIT Kanpur Faculty Entrepreneurship Policy
IISER Kolkata startup policy